393 related articles for article (PubMed ID: 30795583)
1. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
[TBL] [Abstract][Full Text] [Related]
2. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
3. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
Sun L; Huang X; Han J; Cai X; Dai Y; Chu Y; Wang C; Huang W; Qian H
Biochem Pharmacol; 2016 Jun; 110-111():80-91. PubMed ID: 27155328
[TBL] [Abstract][Full Text] [Related]
4. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
[TBL] [Abstract][Full Text] [Related]
5. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
6. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
[TBL] [Abstract][Full Text] [Related]
7. Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites.
Wang M; Yao P; Gao M; Jin J; Yu Y
RSC Adv; 2020 Feb; 10(14):8044-8053. PubMed ID: 35497855
[TBL] [Abstract][Full Text] [Related]
8. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
9. Stapled and
Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J
J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
[TBL] [Abstract][Full Text] [Related]
11. Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals.
Cui J; Shang A; Wang W; Chen W
Life Sci; 2020 Nov; 260():118339. PubMed ID: 32841660
[TBL] [Abstract][Full Text] [Related]
12. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
[TBL] [Abstract][Full Text] [Related]
13. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.
Cai X; Li C; Zhou J; Dai Y; Avraham Y; Sun L; Liu C; Tong J; Wang Y; Bi X; He L; Huang W; Qian H
Bioorg Chem; 2020 Jan; 95():103538. PubMed ID: 31901754
[TBL] [Abstract][Full Text] [Related]
14. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
15. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
16. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
[TBL] [Abstract][Full Text] [Related]
18. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
19. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
[TBL] [Abstract][Full Text] [Related]
20. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
